Furthermore, these patients had significantly lower serum TAGE levels, with increased plasma adiponectin levels and decreased tumor necrosis factor-α (TNF-α) levels in NASH and NAFL patients. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.